Nature's Sunshine Products Inc

Nature's Sunshine Products Inc(NATR)股票分析

$12.840

+0.819 (+6.38%)收盤時

Loading chart…
最高
12.940
開盤
12.340
成交量加權均價
12.70
成交量
123.14K
市值
281.51M
最低
12.320
成交金額
1.56M
企業價值/稅息折舊攤銷前利潤(TTM)
3.91

Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk.

AI 分析 of Nature's Sunshine Products Inc (NATR)

持有

Nature's Sunshine Products Inc (NATR) is currently trading at $12.02, significantly below its 52-week high of $28.14, indicating potential for recovery. However, the stock has a low RSI of 28.072, suggesting it is oversold, but the recent earnings miss and lowered guidance raise concerns about future performance. The forward P/E ratio is 8.87, which is attractive, but the net income has been inconsistent, with a recent drop to $3.54 million in Q2 2026. The main risk is the insider selling, which has increased by 161.97% over the last month, indicating lack of confidence among insiders. Therefore, while there is potential for upside, the current market sentiment and risks suggest holding rather than buying at this time.

估值指標

Nature's Sunshine Products Inc(NATR)目前預期本益比為 8.71,5 年平均預期本益比為 12.41。

預期本益比

合理
5 年均值 P/E
12.41
目前P/E
8.71
高估
57.86
低估
-33.04

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
6.44
目前EV/EBITDA
3.91
高估
9.12
低估
3.77

預期股價營收比

低估
5 年均值 P/S
0.62
目前P/S
0.41
高估
0.76
低估
0.48

Alphio AI 對 NATR 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%NATR

$16.58

情境價格

基

基準

基準 · 50%NATR

$16.06

情境價格

悲

悲觀

悲觀 · 25%NATR

$14.23

情境價格

持有 NATR 的大戶

S

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

+ 持有NATR

-15.12%

3個月報酬率

事件時間軸

2026-11-04 (ET)

17:30:00

Nature's Sunshine Reports Q3 Revenue of $116.6M

17:30:00

Nature's Sunshine Cuts FY26 Adjusted EBITDA Outlook to $44M-$48M

2026-08-06 (ET)

18:30:00

Nature's Sunshine Appoints Ruth Perkins as CFO

2026-05-07 (ET)

17:50:00

Reiterates FY26 Revenue View of $500M-$515M

17:50:00

Company Reports Q1 Revenue of $122.9M

資訊

NATR 常見問題 —— 由 Alphio AI 解答

Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk. It operates in the Consumer Non-Cyclicals sector (PHARMACEUTICAL PREPARATIONS industry).

Nature's Sunshine Products Inc (NATR) is currently trading at $12.02, significantly below its 52-week high of $28.14, indicating potential for recovery. However, the stock has a low RSI of 28.072, suggesting it is oversold, but the recent earnings miss and lowered guidance raise concerns about future performance. The forward P/E ratio is 8.87, which is attractive, but the net income has been inconsistent, with a recent drop to $3.54 million in Q2 2026. The main risk is the insider selling, which has increased by 161.97% over the last month, indicating lack of confidence among insiders. Therefore, while there is potential for upside, the current market sentiment and risks suggest holding rather than buying at this time.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易